As technology evolves, there is potential to quantify and automate presbyopia-correcting IOL selection through measures that ...
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results